Ceregene Initiates Phase 1/2 Trial of CERE-120

Ceregene, Inc., has initiated a new trial of a Parkinson’s drug that may eventually be relevant for ALS. CERE-120 is a gene therapy product that delivers a neurotrophic factor to dying neurons in Parkinson’s patients. Two companies are exploring a similar delivery method for a treatment for ALS and Ceregene also has two potential ALS therapies in its pipeline.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail